ADC Therapeutics SA (ADCT) vs Greenwich LifeSciences (GLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Greenwich LifeSciences (GLSI) has outperformed ADC Therapeutics SA (ADCT) over the past year, gaining 47.9% versus a loss of 65.0%. Over five years, GLSI leads with a -56.5% price change compared with -93.8% for ADCT. Greenwich LifeSciences is the larger company by market cap ($242.6 million vs $220.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | GLSI |
|---|---|---|
| Share price | $1.73 | $16.53 |
| Market cap | $220.87M | $242.63M |
| 1-day change | +8.81% | +9.18% |
| YTD return | -54.96% | -21.32% |
| 1-year return | -64.98% | +47.85% |
| 5-year return | -93.76% | -56.45% |
| EPS (TTM) | $-0.60 | $-1.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.98 | $34.10 |
| 52-week low | $0.78 | $7.78 |
| Distance from 52-week high | -65.26% | -51.52% |
| Analyst consensus | none | none |
| Avg. price target upside | +92.49% | +244.83% |
| Average volume | 1.43M | 138.91K |
| Shares outstanding | 127.67M | 14.68M |
| Employees | 188 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLSI has outperformed ADCT by 112.8 percentage points over the past year.
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
ADCT vs GLSI FAQ
Which is bigger, ADC Therapeutics SA or Greenwich LifeSciences?
Greenwich LifeSciences (GLSI) is larger, with a market capitalization of $242.63M compared with $220.87M for ADC Therapeutics SA (ADCT).
Which stock has performed better over the past year, ADCT or GLSI?
GLSI returned +47.85% over the past 12 months, compared with -64.98% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Are ADC Therapeutics SA and Greenwich LifeSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.